Thalia Therapeutics plc

1. 30 Sep 26
   Half-year Results

   Strategic transformation establishes Thalia as a clinical-stage RNA therapeutics company with a diversified development pipeline

   RNS 9797602 ↗
2. 29 Sep 26
   New Patent Granted for miRisten in China

   Extends intellectual property protection for Thalia’s clinical-stage AML programme

   RNS 9795929 ↗
3. 25 Sep 26
   RNA gene-silencing cardiovascular program advances

   Thalia Therapeutics plc (AIM: THAT), a clinical-stage biotechnology company developing innovative RNA-based therapeutics and delivery technologies in oncology and cardiovascular disease, announces it has completed the initial chemistry synthesis of the...

   RNS 9790260 ↗
4. 15 Sep 26
   Business Update and Notice of Results

   Progress across clinical-stage oncology, cardiovascular and RNA delivery programmes

   RNS 9771620 ↗
5. 23 Jul 26
   Grant of Director Share Options

   Thalia Therapeutics plc (AIM: THAT), a clinical-stage biotechnology company developing innovative RNA-based therapeutics and delivery technologies in oncology and cardiovascular disease, announces that it has granted options over a total of 200,000,000...

   RNS 9684005 ↗
6. 17 Jul 26
   AGM Statement

   Thalia Therapeutics plc (AIM: THAT), a biotechnology company developing innovative RNA-based therapeutics and delivery technologies in oncology and cardiovascular disease, will hold its Annual General Meeting ("AGM") today at 11.00 a.m. at the offices of...

   RNS 9673538 ↗
7. 24 Jun 26
   Acquisition and £2.75 million Fundraise

   Acquisition of oncology company Sanmirna Therapeutics Inc for its clinical-stage Acute Myeloid Leukaemia RNA therapy

   RNS 9633060 ↗
8. 23 Jun 26
   Final Results

   Thalia Therapeutics plc (AIM: THAT), a biotechnology company developing innovative RNA-based therapeutics, in both oncology and cardiovascular disease, as well as broadly applicable delivery technologies, today announces its audited results for the year...

   RNS 9632843 ↗
9. 09 Jun 26
   New article: RNA medicine enters its second act

   New article: RNA medicine enters its second act

   RNS 9607785 ↗
10. 02 Jun 26
    CEO Interview

    CEO Interview: Building a Differentiated RNA Therapeutics Company

    RNS 9597065 ↗
11. 13 May 26
    CEO Interview: Thalia’s RNA Therapeutics Strategy

    Thalia Therapeutics plc (AIM: THAT), a biotech company developing innovative RNA therapeutics, is pleased to announce the release of a new video interview with Chief Executive Officer, Dr David Solomon.

    RNS 9566512 ↗
12. 20 Apr 26
    Change of Registered Address

    Thalia Therapeutics plc (AIM: THAT), the UK biotech developing Nuvec®, its proprietary gene delivery system to enable advanced therapies for cancer and other diseases, announces that it has changed its registered address to 2 Portman Street, London, W1H...

    RNS 9526916 ↗
13. 27 Feb 26
    Notice of GM and Proposed Change of Name

    Notice of General Meeting and Proposed Change of Name to Thalia Therapeutics plc

    RNS 9449926 ↗
14. 24 Feb 26
    CEO Appointment & Name Change Thalia Therapeutics

    CEO Appointment, Strategic Update and Name Change to Thalia Therapeutics

    RNS 9443377 ↗
15. 17 Dec 25
    Business and Operational Update

    N4 Pharma plc (AIM: N4P), the UK biotech developing Nuvec®, its proprietary gene delivery system to enable advanced therapies for cancer and other diseases, is pleased to provide an operational update and business review.

    RNS 9301600 ↗

Source: Investegate RNS archive. Quotes are short extracts. Not investment advice.